Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR1802 in Patients with Chronic Rhinosinusitis with Nasal Polyps
NCT05873803Phase 2Active, not recruiting
- Sponsor
- Zhixiang Jintai
- Start
- Feb 2023
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of telikibart in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Zhixiang Jintai. Started Feb 2023; status: active, not recruiting.
02
Drugs
telikibart
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT05873803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05873803.